143797-63-1
中文名称
1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲
英文名称
SB 200646 HYDROCHLORIDE
CAS
143797-63-1
分子式
C15H14N4O
分子量
266.3
MOL 文件
143797-63-1.mol
更新日期
2025/09/05 13:40:32
143797-63-1 结构式
基本信息
中文别名
化合物SB-2006461-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲
英文别名
SB 200646SB200646HCl
SB 200646 HYDROCHLORIDE
N-(1-methyl-5-indolyl)-N'-(3-pyridyl)urea
N-(1-Methyl-1H-indol-5-yl)-N'-3-pyridinylurea
1-(1-Methyl-1H-indol-5-yl)-3-pyridin-3-yl-urea
Urea, N-(1-methyl-1H-indol-5-yl)-N'-3-pyridinyl-
N-(1-METHYL-1H-INDOL-5-YL)-N'-3-PYRIDINYLUREA HYDROCHLORIDE
N-(1-METHYL-1H-5-INDOLYL)-N'-(3-PYRIDINYL)UREA HYDROCHLORIDE
electrophysiological,5-HT Receptor,SNC,Serotonin Receptor,Inhibitor,antipsychotic,inhibit,5-hydroxytryptamine Receptor,5-HT2B,SB200646,anxiolytic,5-HT2C,neurons,SB 200646,dopaminergic,SB-200646
1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/09/19 | S2649 | 1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲 SB 200646 | 143797-63-1 | 5mg | 2246.13元 |
| 2025/09/19 | S2649 | 1-(1-甲基-1H-吲哚-5-基)-3-(吡啶-3-基)脲 SB 200646 | 143797-63-1 | 25mg | 7366.54元 |
常见问题列表
生物活性
SB 200646 (SB 200646A) 是一种强效的、选择性的 5-HT2B/2C 口服活性拮抗剂，比对5-HT2A受体的选择性高出50倍。SB 200646 对大鼠 5-HT2C 受体、大鼠 5-HT2B 受体和大鼠 5-HT2A 受体的pKi值分别为6.9、7.5和5.2。SB 200646 在体内具有电生理作用和抗焦虑的特性。靶点
| Target | Value |
|
5-HT2B (rat)
(Cell-free assay) | 7.5(pKi) |
|
5-HT2C (Rat)
(Cell-free assay) | 6.9(pKi) |
|
5-HT2A (rat)
(Cell-free assay) | 5.2(pKi) |
体外研究
SB-200646A (4 μM) abolishes the ethanol-induced increase in miniature inhibitory postsynaptic current (mIPSC) frequency and had no effect on basal mIPSC frequency.
体内研究
SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons.
The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons.
| Animal Model: | Male albino Sprague-Dawley rats (200-225 g at the beginning of treatment and 300-350 g at the time of the experiment) |
| Dosage: | 20 mg/kg |
| Administration: | Intravenous injection; daily; for 21 days |
| Result: | Significantly decreased the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons. |